Cargando…
Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment
BACKGROUND: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623922/ https://www.ncbi.nlm.nih.gov/pubmed/26502900 http://dx.doi.org/10.1186/s13023-015-0358-y |
_version_ | 1782397762561638400 |
---|---|
author | Serrano, Mercedes de Diego, Víctor Muchart, Jordi Cuadras, Daniel Felipe, Ana Macaya, Alfons Velázquez, Ramón Poo, M. Pilar Fons, Carmen O’Callaghan, M. Mar García-Cazorla, Angels Boix, Cristina Robles, Bernabé Carratalá, Francisco Girós, Marisa Briones, Paz Gort, Laura Artuch, Rafael Pérez-Cerdá, Celia Jaeken, Jaak Pérez, Belén Pérez-Dueñas, Belén |
author_facet | Serrano, Mercedes de Diego, Víctor Muchart, Jordi Cuadras, Daniel Felipe, Ana Macaya, Alfons Velázquez, Ramón Poo, M. Pilar Fons, Carmen O’Callaghan, M. Mar García-Cazorla, Angels Boix, Cristina Robles, Bernabé Carratalá, Francisco Girós, Marisa Briones, Paz Gort, Laura Artuch, Rafael Pérez-Cerdá, Celia Jaeken, Jaak Pérez, Belén Pérez-Dueñas, Belén |
author_sort | Serrano, Mercedes |
collection | PubMed |
description | BACKGROUND: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction. We aim to assess the validity of the International Cooperative Ataxia Rating Scale (ICARS) in children and adolescents with genetically confirmed PMM2-CDG deficiency. We compare ICARS results with the Nijmegen Pediatric CDG Rating Scale (NPCRS), neuroimaging, intelligence quotient (IQ) and molecular data. METHODS: Our observational study included 13 PMM2-CDG patients and 21 control subjects. Ethical permissions and informed consents were obtained. Three independent child neurologists rated PMM2-CDG patients and control subjects using the ICARS. A single clinician administered the NPCRS. All patients underwent brain MRI, and the relative diameter of the midsagittal vermis was measured. Psychometric evaluations were available in six patients. The Mann–Whitney U test was used to compare ICARS between patients and controls. To evaluate inter-observer agreement in patients’ ICARS ratings, intraclass correlation coefficients (ICC) were calculated. ICARS internal consistency was evaluated using Cronbach’s alpha. Spearman’s rank correlation coefficient test was used to correlate ICARS with NPCRS, midsagittal vermis relative diameter and IQ. RESULTS: ICARS and ICARS subscores differed between patients and controls (p < 0.001). Interobserver agreement of ICARS was “almost perfect” (ICC = 0.99), with a “good” internal reliability (Cronbach’s alpha = 0.72). ICARS was significantly correlated with the total NPCRS score (r(s) 0.90, p < 0.001). However, there was no agreement regarding categories of severity. Regarding neuroimaging, inverse correlations between ICARS and midsagittal vermis relative diameter (r(s) −0.85, p = 0.003) and IQ (r(s) −0.94, p = 0.005) were found. Patients bearing p.E93A, p.C241S or p.R162W mutations presented a milder phenotype. CONCLUSIONS: ICARS is a reliable instrument for assessment of PMM2-CDG patients, without significant inter-rater variability. Despite our limited sample size, the results show a good correlation between functional cerebellar assessment, IQ and neuroimagingFor the first a correlation between ICARS, neuroimaging and IQ in PMM2-CDG patients has been demonstrated. |
format | Online Article Text |
id | pubmed-4623922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46239222015-10-29 Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment Serrano, Mercedes de Diego, Víctor Muchart, Jordi Cuadras, Daniel Felipe, Ana Macaya, Alfons Velázquez, Ramón Poo, M. Pilar Fons, Carmen O’Callaghan, M. Mar García-Cazorla, Angels Boix, Cristina Robles, Bernabé Carratalá, Francisco Girós, Marisa Briones, Paz Gort, Laura Artuch, Rafael Pérez-Cerdá, Celia Jaeken, Jaak Pérez, Belén Pérez-Dueñas, Belén Orphanet J Rare Dis Research BACKGROUND: Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction. We aim to assess the validity of the International Cooperative Ataxia Rating Scale (ICARS) in children and adolescents with genetically confirmed PMM2-CDG deficiency. We compare ICARS results with the Nijmegen Pediatric CDG Rating Scale (NPCRS), neuroimaging, intelligence quotient (IQ) and molecular data. METHODS: Our observational study included 13 PMM2-CDG patients and 21 control subjects. Ethical permissions and informed consents were obtained. Three independent child neurologists rated PMM2-CDG patients and control subjects using the ICARS. A single clinician administered the NPCRS. All patients underwent brain MRI, and the relative diameter of the midsagittal vermis was measured. Psychometric evaluations were available in six patients. The Mann–Whitney U test was used to compare ICARS between patients and controls. To evaluate inter-observer agreement in patients’ ICARS ratings, intraclass correlation coefficients (ICC) were calculated. ICARS internal consistency was evaluated using Cronbach’s alpha. Spearman’s rank correlation coefficient test was used to correlate ICARS with NPCRS, midsagittal vermis relative diameter and IQ. RESULTS: ICARS and ICARS subscores differed between patients and controls (p < 0.001). Interobserver agreement of ICARS was “almost perfect” (ICC = 0.99), with a “good” internal reliability (Cronbach’s alpha = 0.72). ICARS was significantly correlated with the total NPCRS score (r(s) 0.90, p < 0.001). However, there was no agreement regarding categories of severity. Regarding neuroimaging, inverse correlations between ICARS and midsagittal vermis relative diameter (r(s) −0.85, p = 0.003) and IQ (r(s) −0.94, p = 0.005) were found. Patients bearing p.E93A, p.C241S or p.R162W mutations presented a milder phenotype. CONCLUSIONS: ICARS is a reliable instrument for assessment of PMM2-CDG patients, without significant inter-rater variability. Despite our limited sample size, the results show a good correlation between functional cerebellar assessment, IQ and neuroimagingFor the first a correlation between ICARS, neuroimaging and IQ in PMM2-CDG patients has been demonstrated. BioMed Central 2015-10-26 /pmc/articles/PMC4623922/ /pubmed/26502900 http://dx.doi.org/10.1186/s13023-015-0358-y Text en © Serrano et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Serrano, Mercedes de Diego, Víctor Muchart, Jordi Cuadras, Daniel Felipe, Ana Macaya, Alfons Velázquez, Ramón Poo, M. Pilar Fons, Carmen O’Callaghan, M. Mar García-Cazorla, Angels Boix, Cristina Robles, Bernabé Carratalá, Francisco Girós, Marisa Briones, Paz Gort, Laura Artuch, Rafael Pérez-Cerdá, Celia Jaeken, Jaak Pérez, Belén Pérez-Dueñas, Belén Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment |
title | Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment |
title_full | Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment |
title_fullStr | Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment |
title_full_unstemmed | Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment |
title_short | Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment |
title_sort | phosphomannomutase deficiency (pmm2-cdg): ataxia and cerebellar assessment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623922/ https://www.ncbi.nlm.nih.gov/pubmed/26502900 http://dx.doi.org/10.1186/s13023-015-0358-y |
work_keys_str_mv | AT serranomercedes phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT dediegovictor phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT muchartjordi phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT cuadrasdaniel phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT felipeana phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT macayaalfons phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT velazquezramon phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT poompilar phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT fonscarmen phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT ocallaghanmmar phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT garciacazorlaangels phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT boixcristina phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT roblesbernabe phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT carratalafrancisco phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT girosmarisa phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT brionespaz phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT gortlaura phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT artuchrafael phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT perezcerdacelia phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT jaekenjaak phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT perezbelen phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment AT perezduenasbelen phosphomannomutasedeficiencypmm2cdgataxiaandcerebellarassessment |